Provention Bio Inc. (NASDAQ: PRVB) is 14.82% higher on its value in year-to-date trading and has touched a low of $4.72 and a high of $20.05 in the current 52-week trading range. The PRVB stock was last observed hovering at around $19.45 in the last trading session, with the day’s loss setting it -3.04% off its average median price target of $27.00 for the next 12 months. It is also 58.98% off the consensus price target high of $40.00 offered by 7 analysts, but current levels are 34.36% higher than the price target low of $25.00 for the same period.
Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.
Currently trading at $16.41, the stock is -8.35% and 1.98% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.24 million and changing -15.63% at the moment leaves the stock 21.24% off its SMA200. PRVB registered 23.10% gain for a year compared to 6-month gain of 59.56%. The firm has a 50-day simple moving average (SMA 50) of $17.16 and a 200-day simple moving average (SMA200) of $14.03.
The stock witnessed a 11.40% loss in the last 1 month and extending the period to 3 months gives it a 41.15%, and is 11.21% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.37% over the week and 5.74% over the month.
Distance from 52-week low is 247.67% and -18.15% from its 52-week high.
Provention Bio Inc. (PRVB) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Provention Bio Inc. (PRVB) is a “Buy”. 7 analysts offering their recommendations for the stock have an average rating of 1.70, where 0 rate it as a Hold and 1 think it is a “Overweight”. 6 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Provention Bio Inc. is expected to release its quarterly report on 05/13/2021 and quarterly earnings per share for the current quarter are estimated at -$0.5.The EPS is expected to shrink by -34.50% this year.
Provention Bio Inc. (PRVB) Top Institutional Holders
140 institutions hold shares in Provention Bio Inc. (PRVB), with 10.31M shares held by insiders accounting for 18.25% while institutional investors hold 52.38% of the company’s shares. The shares outstanding are 56.34M, and float is at 41.91M with Short Float at 7.84%. Institutions hold 42.81% of the Float.
The top institutional shareholder in the company is Perceptive Advisors Llc with over 4.27 million shares valued at $54.73 million. The investor’s holdings represent 7.55% of the PRVB Shares outstanding. As of Sep 29, 2020, the second largest holder is Blackrock Inc. with 3.31 million shares valued at $42.52 million to account for 5.87% of the shares outstanding. The other top investors are Vanguard Group, Inc. (The) which holds 2.2 million shares representing 3.90% and valued at over $28.23 million, while Gilder, Gagnon, Howe & Co. holds 3.81% of the shares totaling 2.15 million with a market value of $27.6 million.
Provention Bio Inc. (PRVB) Insider Activity
A total of 7 insider transactions have happened at Provention Bio Inc. (PRVB) in the last six months, with sales accounting for 0 and purchases happening 7 times. The most recent transaction is an insider purchase by Drechsler Andrew T, the company’s Chief Financial Officer. SEC filings show that Drechsler Andrew T bought 2,000 shares of the company’s common stock on Sep 02 at a price of $11.72 per share for a total of $23440.0. Following the purchase, the insider now owns 20000.0 shares.
Provention Bio Inc. disclosed in a document filed with the SEC on Sep 02 that Ramos Eleanor (Chief Medical Officer) bought a total of 299 shares of the company’s common stock. The trade occurred on Sep 02 and was made at $12.06 per share for $3606.0. Following the transaction, the insider now directly holds 64799.0 shares of the PRVB stock.
Still, SEC filings show that on Aug 21, Leon Francisco (Chief Scientific Officer) acquired 2,000 shares at an average price of $13.35 for $26708.0. The insider now directly holds 2,567,450 shares of Provention Bio Inc. (PRVB).